+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Mexoryl SX Market By Purity Level, By Application: Global Opportunity Analysis and Industry Forecast, 2021-2031

  • PDF Icon

    Report

  • 199 Pages
  • July 2022
  • Region: Global
  • Allied Market Research
  • ID: 5671165
The global mexoryl SX (ecamsule) market was valued at $49.5 million in 2021, and is projected to reach $82.6 million by 2031, growing at a CAGR of 5.3% from 2022 to 2031.

Mexoryl SX is the trade name for ecamsule, or terephthalylidene dicamphor sulfonic acid. It is an organic sun filter (carbon-based) developed and patented by L'Oréal in 1982. It protects mainly against UVA rays, the main cause of premature skin aging and skin cancers. In addition, it is used as a photostable drug that resists the formation of UV induced pyrimidine dimers and delays the onset of skin cancer.

The increasing awareness toward skincare, beauty, and lifestyle has surged the demand for personal care & cosmetic products where mexoryl SX (ecamsule) protects skin mainly from long wave ultraviolet A (UVA) rays that is the main cause of premature skin aging and skin cancers. This may propel the growth of the mexoryl SX) ecamsule) market. In addition, rise in concerns about skin protection against detrimental rays of the sun and improved alertness regarding skin cancer have led the customers become more linear toward using mexoryl SX (ecamsule)-based sunscreens, which fosters the growth of the mexoryl SX (ecamsule) market.

However, mexoryl SX (ecamsule) is a newly developed product and is relatively new in the market. It requires certain testing and approvals for its adoption among various end use applications. For instance, food and drug administration (FDA) is proposing to prevent the use of ecamsule and anzacamene in sunscreens due to their ineffectiveness. Thus, FDA’s action means that Americans may not have access to these products. This factor may hamper the growth of the mexoryl SX (ecamsule) market during the forecast period.

On the contrary, surge in R&D activities for developing a broad spectrum of sunscreens formulation where mexoryl SX (ecamsule) is widely used for photo-protection purposes in all skin types may create new opportunities for the market.

The mexoryl SX (ecamsule) market is segmented into purity level, application, and region. On the basis of purity level, the market is segregated into less than 98% and more than 98%. Depending on application, it is fragmented into cosmetics, phamraceuticals, and others. Region wise, the market is studied across North America, Europe, Asia-Pacific, and LAMEA.

The leading players operating in the global mexoryl SX (ecamsule) market include Biosynth Carbosynth, ChemScene LLC, Derma Company, National Analytical Corporation, Norna Technology Co., Skylead Pharmaceuticals & Chemicals, L'Oréal S.A., and MFCI CO.,LTD (Hubei Meifeng Chemical Co., Ltd.). The global mexoryl SX (ecamsule) market report provides in-depth competitive analysis as well as profiles of these major players.

KEY BENEFITS FOR STAKEHOLDERS

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the mexoryl sx (ecamsule) market analysis from 2021 to 2031 to identify the prevailing mexoryl sx (ecamsule) market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the mexoryl sx (ecamsule) market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global mexoryl sx (ecamsule) market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Purity Level

  • Less than 98%
  • More than 98%

By Application

  • Cosmetics
  • Pharmaceuticals
  • Others

By Region

  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • Germany
  • United Kingdom
  • France
  • Spain
  • Italy
  • Rest of Europe
  • Asia-Pacific
  • Australia
  • Rest of Asia-Pacific
  • China
  • India
  • Japan
  • South Korea
  • LAMEA
  • Brazil
  • Saudi Arabia
  • South Africa
  • Rest of LAMEA

Key Market Players

  • L'Oréal S.A.
  • Skylead Pharmaceuticals & Chemicals
  • ChemScene LLC
  • Biosynth Carbosynth
  • NATIONAL ANALYTICAL CORPORATION
  • Norna Technology Co.
  • Derma Companies
  • MFCI CO.,LTD
  • Merck KGaA
  • Parchem Fine and Specialty Chemicals

Table of Contents

CHAPTER 1: INTRODUCTION
1.1.Report description
1.2.Key market segments
1.3.Key benefits to the stakeholders
1.4.Research Methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO Perspective
CHAPTER 3: MARKET OVERVIEW
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.3.Porter’s five forces analysis
3.4.Top player positioning
3.5.Market dynamics
3.5.1.Drivers
3.5.2.Restraints
3.5.3.Opportunities
3.6.COVID-19 Impact Analysis on the market
3.7.Pricing Analysis
3.8.Value Chain Analysis
3.9.Key Regulation Analysis
3.10.Patent Landscape
CHAPTER 4: MEXORYL SX (ECAMSULE) MARKET, BY PURITY LEVEL
4.1 Overview
4.1.1 Market size and forecast
4.2 Less than 98%
4.2.1 Key market trends, growth factors and opportunities
4.2.2 Market size and forecast, by region
4.2.3 Market analysis by country
4.3 More than 98%
4.3.1 Key market trends, growth factors and opportunities
4.3.2 Market size and forecast, by region
4.3.3 Market analysis by country
CHAPTER 5: MEXORYL SX (ECAMSULE) MARKET, BY APPLICATION
5.1 Overview
5.1.1 Market size and forecast
5.2 Cosmetics
5.2.1 Key market trends, growth factors and opportunities
5.2.2 Market size and forecast, by region
5.2.3 Market analysis by country
5.3 Pharmaceuticals
5.3.1 Key market trends, growth factors and opportunities
5.3.2 Market size and forecast, by region
5.3.3 Market analysis by country
5.4 Others
5.4.1 Key market trends, growth factors and opportunities
5.4.2 Market size and forecast, by region
5.4.3 Market analysis by country
CHAPTER 6: MEXORYL SX (ECAMSULE) MARKET, BY REGION
6.1 Overview
6.1.1 Market size and forecast
6.2 North America
6.2.1 Key trends and opportunities
6.2.2 North America Market size and forecast, by Purity Level
6.2.3 North America Market size and forecast, by Application
6.2.4 North America Market size and forecast, by country
6.2.4.1 U.S.
6.2.4.1.1 Market size and forecast, by Purity Level
6.2.4.1.2 Market size and forecast, by Application
6.2.4.2 Canada
6.2.4.2.1 Market size and forecast, by Purity Level
6.2.4.2.2 Market size and forecast, by Application
6.2.4.3 Mexico
6.2.4.3.1 Market size and forecast, by Purity Level
6.2.4.3.2 Market size and forecast, by Application
6.3 Europe
6.3.1 Key trends and opportunities
6.3.2 Europe Market size and forecast, by Purity Level
6.3.3 Europe Market size and forecast, by Application
6.3.4 Europe Market size and forecast, by country
6.3.4.1 Germany
6.3.4.1.1 Market size and forecast, by Purity Level
6.3.4.1.2 Market size and forecast, by Application
6.3.4.2 United Kingdom
6.3.4.2.1 Market size and forecast, by Purity Level
6.3.4.2.2 Market size and forecast, by Application
6.3.4.3 France
6.3.4.3.1 Market size and forecast, by Purity Level
6.3.4.3.2 Market size and forecast, by Application
6.3.4.4 Spain
6.3.4.4.1 Market size and forecast, by Purity Level
6.3.4.4.2 Market size and forecast, by Application
6.3.4.5 Italy
6.3.4.5.1 Market size and forecast, by Purity Level
6.3.4.5.2 Market size and forecast, by Application
6.3.4.6 Rest of Europe
6.3.4.6.1 Market size and forecast, by Purity Level
6.3.4.6.2 Market size and forecast, by Application
6.4 Asia-Pacific
6.4.1 Key trends and opportunities
6.4.2 Asia-Pacific Market size and forecast, by Purity Level
6.4.3 Asia-Pacific Market size and forecast, by Application
6.4.4 Asia-Pacific Market size and forecast, by country
6.4.4.1 China
6.4.4.1.1 Market size and forecast, by Purity Level
6.4.4.1.2 Market size and forecast, by Application
6.4.4.2 India
6.4.4.2.1 Market size and forecast, by Purity Level
6.4.4.2.2 Market size and forecast, by Application
6.4.4.3 Japan
6.4.4.3.1 Market size and forecast, by Purity Level
6.4.4.3.2 Market size and forecast, by Application
6.4.4.4 South Korea
6.4.4.4.1 Market size and forecast, by Purity Level
6.4.4.4.2 Market size and forecast, by Application
6.4.4.5 Australia
6.4.4.5.1 Market size and forecast, by Purity Level
6.4.4.5.2 Market size and forecast, by Application
6.4.4.6 Rest of Asia-Pacific
6.4.4.6.1 Market size and forecast, by Purity Level
6.4.4.6.2 Market size and forecast, by Application
6.5 LAMEA
6.5.1 Key trends and opportunities
6.5.2 LAMEA Market size and forecast, by Purity Level
6.5.3 LAMEA Market size and forecast, by Application
6.5.4 LAMEA Market size and forecast, by country
6.5.4.1 Brazil
6.5.4.1.1 Market size and forecast, by Purity Level
6.5.4.1.2 Market size and forecast, by Application
6.5.4.2 Saudi Arabia
6.5.4.2.1 Market size and forecast, by Purity Level
6.5.4.2.2 Market size and forecast, by Application
6.5.4.3 South Africa
6.5.4.3.1 Market size and forecast, by Purity Level
6.5.4.3.2 Market size and forecast, by Application
6.5.4.4 Rest of LAMEA
6.5.4.4.1 Market size and forecast, by Purity Level
6.5.4.4.2 Market size and forecast, by Application
CHAPTER 7: COMPANY LANDSCAPE
7.1. Introduction
7.2. Top winning strategies
7.3. Product Mapping of Top 10 Player
7.4. Competitive Dashboard
7.5. Competitive Heatmap
7.6. Key developments
CHAPTER 8: COMPANY PROFILES
8.1 L'Oréal S.A.
8.1.1 Company overview
8.1.2 Company snapshot
8.1.3 Operating business segments
8.1.4 Product portfolio
8.1.5 Business performance
8.1.6 Key strategic moves and developments
8.2 Skylead Pharmaceuticals & Chemicals
8.2.1 Company overview
8.2.2 Company snapshot
8.2.3 Operating business segments
8.2.4 Product portfolio
8.2.5 Business performance
8.2.6 Key strategic moves and developments
8.3 ChemScene LLC
8.3.1 Company overview
8.3.2 Company snapshot
8.3.3 Operating business segments
8.3.4 Product portfolio
8.3.5 Business performance
8.3.6 Key strategic moves and developments
8.4 Biosynth Carbosynth
8.4.1 Company overview
8.4.2 Company snapshot
8.4.3 Operating business segments
8.4.4 Product portfolio
8.4.5 Business performance
8.4.6 Key strategic moves and developments
8.5 NATIONAL ANALYTICAL CORPORATION
8.5.1 Company overview
8.5.2 Company snapshot
8.5.3 Operating business segments
8.5.4 Product portfolio
8.5.5 Business performance
8.5.6 Key strategic moves and developments
8.6 Norna Technology Co.
8.6.1 Company overview
8.6.2 Company snapshot
8.6.3 Operating business segments
8.6.4 Product portfolio
8.6.5 Business performance
8.6.6 Key strategic moves and developments
8.7 Derma Companies
8.7.1 Company overview
8.7.2 Company snapshot
8.7.3 Operating business segments
8.7.4 Product portfolio
8.7.5 Business performance
8.7.6 Key strategic moves and developments
8.8 MFCI CO.,LTD
8.8.1 Company overview
8.8.2 Company snapshot
8.8.3 Operating business segments
8.8.4 Product portfolio
8.8.5 Business performance
8.8.6 Key strategic moves and developments
8.9 Merck KGaA
8.9.1 Company overview
8.9.2 Company snapshot
8.9.3 Operating business segments
8.9.4 Product portfolio
8.9.5 Business performance
8.9.6 Key strategic moves and developments
8.10 Parchem Fine and Specialty Chemicals
8.10.1 Company overview
8.10.2 Company snapshot
8.10.3 Operating business segments
8.10.4 Product portfolio
8.10.5 Business performance
8.10.6 Key strategic moves and developments
List of Tables
Table 1. Global Intravenous Solutions Market, by Type, 2021-2031 ($Million)
Table 2. Intravenous Solutions Market Size, for Partial Parenteral Nutrition, by Region, 2021-2031 ($Million)
Table 3. Intravenous Solutions Market for Partial Parenteral Nutrition, by Country, 2021-2031 ($Million)
Table 4. Global Partial Parenteral Nutrition Intravenous Solutions Market, by Age Group, 2021-2031 ($Million)
Table 5. Intravenous Solutions Market Size, for Total Parenteral Nutrition, by Region, 2021-2031 ($Million)
Table 6. Intravenous Solutions Market for Total Parenteral Nutrition, by Country, 2021-2031 ($Million)
Table 7. Global Total Parenteral Nutrition Intravenous Solutions Market, by Age Group, 2021-2031 ($Million)
Table 8. Global Intravenous Solutions Market, by Composition, 2021-2031 ($Million)
Table 9. Intravenous Solutions Market Size, for Carbohydrates, by Region, 2021-2031 ($Million)
Table 10. Intravenous Solutions Market for Carbohydrates, by Country, 2021-2031 ($Million)
Table 11. Intravenous Solutions Market Size, for Vitamins and Minerals, by Region, 2021-2031 ($Million)
Table 12. Intravenous Solutions Market for Vitamins and Minerals, by Country, 2021-2031 ($Million)
Table 13. Intravenous Solutions Market Size, for Single Dose Amino Acids, by Region, 2021-2031 ($Million)
Table 14. Intravenous Solutions Market for Single Dose Amino Acids, by Country, 2021-2031 ($Million)
Table 15. Intravenous Solutions Market Size, for Parenteral Lipid Emulsion, by Region, 2021-2031 ($Million)
Table 16. Intravenous Solutions Market for Parenteral Lipid Emulsion, by Country, 2021-2031 ($Million)
Table 17. Intravenous Solutions Market Size, for Others, by Region, 2021-2031 ($Million)
Table 18. Intravenous Solutions Market for Others, by Country, 2021-2031 ($Million)
Table 19. Global Intravenous Solutions Market, by End-users, 2021-2031 ($Million)
Table 20. Intravenous Solutions Market Size, for Hospitals and Clinics, by Region, 2021-2031 ($Million)
Table 21. Intravenous Solutions Market for Hospitals and Clinics, by Country, 2021-2031 ($Million)
Table 22. Intravenous Solutions Market Size, for Ambulatory Surgery Centers, by Region, 2021-2031 ($Million)
Table 23. Intravenous Solutions Market for Ambulatory Surgery Centers, by Country, 2021-2031 ($Million)
Table 24. Intravenous Solutions Market Size, for Home Care Settings, by Region, 2021-2031 ($Million)
Table 25. Intravenous Solutions Market for Home Care Settings, by Country, 2021-2031 ($Million)
Table 26. Intravenous Solutions Market, by Region, 2021-2031 ($Million)
Table 27. North America Intravenous Solutions Market, by Type, 2021-2031 ($Million)
Table 28. North America Intravenous Solutions Market, by Composition, 2021-2031 ($Million)
Table 29. North America Intravenous Solutions Market, by End-users, 2021-2031 ($Million)
Table 30. North America Intravenous Solutions Market, by Country, 2021-2031 ($Million)
Table 31. U.S. Intravenous Solutions Market, by Type, 2021-2031 ($Million)
Table 32. U.S. Intravenous Solutions Market, by Composition, 2021-2031 ($Million)
Table 33. U.S. Intravenous Solutions Market, by End-users, 2021-2031 ($Million)
Table 34. Canada Intravenous Solutions Market, by Type, 2021-2031 ($Million)
Table 35. Canada Intravenous Solutions Market, by Composition, 2021-2031 ($Million)
Table 36. Canada Intravenous Solutions Market, by End-users, 2021-2031 ($Million)
Table 37. Mexico Intravenous Solutions Market, by Type, 2021-2031 ($Million)
Table 38. Mexico Intravenous Solutions Market, by Composition, 2021-2031 ($Million)
Table 39. Mexico Intravenous Solutions Market, by End-users, 2021-2031 ($Million)
Table 40. Europe Intravenous Solutions Market, by Type, 2021-2031 ($Million)
Table 41. Europe Intravenous Solutions Market, by Composition, 2021-2031 ($Million)
Table 42. Europe Intravenous Solutions Market, by End-users, 2021-2031 ($Million)
Table 43. Europe Intravenous Solutions Market, by Country, 2021-2031 ($Million)
Table 44. Germany Intravenous Solutions Market, by Type, 2021-2031 ($Million)
Table 45. Germany Intravenous Solutions Market, by Composition, 2021-2031 ($Million)
Table 46. Germany Intravenous Solutions Market, by End-users, 2021-2031 ($Million)
Table 47. France Intravenous Solutions Market, by Type, 2021-2031 ($Million)
Table 48. France Intravenous Solutions Market, by Composition, 2021-2031 ($Million)
Table 49. France Intravenous Solutions Market, by End-users, 2021-2031 ($Million)
Table 50. UK Intravenous Solutions Market, by Type, 2021-2031 ($Million)
Table 51. UK Intravenous Solutions Market, by Composition, 2021-2031 ($Million)
Table 52. UK Intravenous Solutions Market, by End-users, 2021-2031 ($Million)
Table 53. Italy Intravenous Solutions Market, by Type, 2021-2031 ($Million)
Table 54. Italy Intravenous Solutions Market, by Composition, 2021-2031 ($Million)
Table 55. Italy Intravenous Solutions Market, by End-users, 2021-2031 ($Million)
Table 56. Spain Intravenous Solutions Market, by Type, 2021-2031 ($Million)
Table 57. Spain Intravenous Solutions Market, by Composition, 2021-2031 ($Million)
Table 58. Spain Intravenous Solutions Market, by End-users, 2021-2031 ($Million)
Table 59. Rest of Europe Intravenous Solutions Market, by Type, 2021-2031 ($Million)
Table 60. Rest of Europe Intravenous Solutions Market, by Composition, 2021-2031 ($Million)
Table 61. Rest of Europe Intravenous Solutions Market, by End-users, 2021-2031 ($Million)
Table 62. Asia-Pacific Intravenous Solutions Market, by Type, 2021-2031 ($Million)
Table 63. Asia-Pacific Intravenous Solutions Market, by Composition, 2021-2031 ($Million)
Table 64. Asia-Pacific Intravenous Solutions Market, by End-users, 2021-2031 ($Million)
Table 65. Asia-Pacific Intravenous Solutions Market, by Country, 2021-2031 ($Million)
Table 66. Japan Intravenous Solutions Market, by Type, 2021-2031 ($Million)
Table 67. Japan Intravenous Solutions Market, by Composition, 2021-2031 ($Million)
Table 68. Japan Intravenous Solutions Market, by End-users, 2021-2031 ($Million)
Table 69. China Intravenous Solutions Market, by Type, 2021-2031 ($Million)
Table 70. China Intravenous Solutions Market, by Composition, 2021-2031 ($Million)
Table 71. China Intravenous Solutions Market, by End-users, 2021-2031 ($Million)
Table 72. India Intravenous Solutions Market, by Type, 2021-2031 ($Million)
Table 73. India Intravenous Solutions Market, by Composition, 2021-2031 ($Million)
Table 74. India Intravenous Solutions Market, by End-users, 2021-2031 ($Million)
Table 75. Australia Intravenous Solutions Market, by Type, 2021-2031 ($Million)
Table 76. Australia Intravenous Solutions Market, by Composition, 2021-2031 ($Million)
Table 77. Australia Intravenous Solutions Market, by End-users, 2021-2031 ($Million)
Table 78. South Korea Intravenous Solutions Market, by Type, 2021-2031 ($Million)
Table 79. South Korea Intravenous Solutions Market, by Composition, 2021-2031 ($Million)
Table 80. South Korea Intravenous Solutions Market, by End-users, 2021-2031 ($Million)
Table 81. Taiwan Intravenous Solutions Market, by Type, 2021-2031 ($Million)
Table 82. Taiwan Intravenous Solutions Market, by Composition, 2021-2031 ($Million)
Table 83. Taiwan Intravenous Solutions Market, by End-users, 2021-2031 ($Million)
Table 84. Rest of Asia-Pacific Intravenous Solutions Market, by Type, 2021-2031 ($Million)
Table 85. Rest of Asia-Pacific Intravenous Solutions Market, by Composition, 2021-2031 ($Million)
Table 86. Rest of Asia-Pacific Intravenous Solutions Market, by End-users, 2021-2031 ($Million)
Table 87. LAMEA Intravenous Solutions Market, by Type, 2021-2031 ($Million)
Table 88. LAMEA Intravenous Solutions Market, by Composition, 2021-2031 ($Million)
Table 89. LAMEA Intravenous Solutions Market, by End-users, 2021-2031 ($Million)
Table 90. LAMEA Intravenous Solutions Market, by Country, 2021-2031 ($Million)
Table 91. Brazil Intravenous Solutions Market, by Type, 2021-2031 ($Million)
Table 92. Brazil Intravenous Solutions Market, by Composition, 2021-2031 ($Million)
Table 93. Brazil Intravenous Solutions Market, by End-users, 2021-2031 ($Million)
Table 94. Turkey Intravenous Solutions Market, by Type, 2021-2031 ($Million)
Table 95. Turkey Intravenous Solutions Market, by Composition, 2021-2031 ($Million)
Table 96. Turkey Intravenous Solutions Market, by End-users, 2021-2031 ($Million)
Table 97. Venezuela Intravenous Solutions Market, by Type, 2021-2031 ($Million)
Table 98. Venezuela Intravenous Solutions Market, by Composition, 2021-2031 ($Million)
Table 99. Venezuela Intravenous Solutions Market, by End-users, 2021-2031 ($Million)
Table 100. Saudi Arabia Intravenous Solutions Market, by Type, 2021-2031 ($Million)
Table 101. Saudi Arabia Intravenous Solutions Market, by Composition, 2021-2031 ($Million)
Table 102. Saudi Arabia Intravenous Solutions Market, by End-users, 2021-2031 ($Million)
Table 103. South Africa Intravenous Solutions Market, by Type, 2021-2031 ($Million)
Table 104. South Africa Intravenous Solutions Market, by Composition, 2021-2031 ($Million)
Table 105. South Africa Intravenous Solutions Market, by End-users, 2021-2031 ($Million)
Table 106. Rest of LAMEA Intravenous Solutions Market, by Type, 2021-2031 ($Million)
Table 107. Rest of LAMEA Intravenous Solutions Market, by Composition, 2021-2031 ($Million)
Table 108. Rest of LAMEA Intravenous Solutions Market, by End-users, 2021-2031 ($Million)
Table 109. Amanta Healthcare Ltd.: Company Snapshot
Table 110. Amanta Healthcare Ltd.: Operating Segments
Table 111. Amanta Healthcare Ltd.: Product Portfolio
Table 112. Amanta Healthcare Ltd.: Net Sales
Table 113. Amanta Healthcare Ltd.: Key Stratergies
Table 114. Axa Parenterals Ltd.: Company Snapshot
Table 115. Axa Parenterals Ltd.: Operating Segments
Table 116. Axa Parenterals Ltd.: Product Portfolio
Table 117. Axa Parenterals Ltd.: Net Sales
Table 118. Axa Parenterals Ltd.: Key Stratergies
Table 119. B. Braun Melsungen Ag: Company Snapshot
Table 120. B. Braun Melsungen Ag: Operating Segments
Table 121. B. Braun Melsungen Ag: Product Portfolio
Table 122. B. Braun Melsungen Ag: Net Sales
Table 123. B. Braun Melsungen Ag: Key Stratergies
Table 124. Baxter International Inc.: Company Snapshot
Table 125. Baxter International Inc.: Operating Segments
Table 126. Baxter International Inc.: Product Portfolio
Table 127. Baxter International Inc.: Net Sales
Table 128. Baxter International Inc.: Key Stratergies
Table 129. Becton, Dickinson and Company: Company Snapshot
Table 130. Becton, Dickinson and Company: Operating Segments
Table 131. Becton, Dickinson and Company: Product Portfolio
Table 132. Becton, Dickinson and Company: Net Sales
Table 133. Becton, Dickinson and Company: Key Stratergies
Table 134. Eurolife Healthcare Pvt Ltd.: Company Snapshot
Table 135. Eurolife Healthcare Pvt Ltd.: Operating Segments
Table 136. Eurolife Healthcare Pvt Ltd.: Product Portfolio
Table 137. Eurolife Healthcare Pvt Ltd.: Net Sales
Table 138. Eurolife Healthcare Pvt Ltd.: Key Stratergies
Table 139. Fresenius Kabi Ag: Company Snapshot
Table 140. Fresenius Kabi Ag: Operating Segments
Table 141. Fresenius Kabi Ag: Product Portfolio
Table 142. Fresenius Kabi Ag: Net Sales
Table 143. Fresenius Kabi Ag: Key Stratergies
Table 144. Grifols S.A: Company Snapshot
Table 145. Grifols S.A: Operating Segments
Table 146. Grifols S.A: Product Portfolio
Table 147. Grifols S.A: Net Sales
Table 148. Grifols S.A: Key Stratergies
Table 149. Henry Schein Inc.: Company Snapshot
Table 150. Henry Schein Inc.: Operating Segments
Table 151. Henry Schein Inc.: Product Portfolio
Table 152. Henry Schein Inc.: Net Sales
Table 153. Henry Schein Inc.: Key Stratergies
Table 154. Icu Medical, Inc.: Company Snapshot
Table 155. Icu Medical, Inc.: Operating Segments
Table 156. Icu Medical, Inc.: Product Portfolio
Table 157. Icu Medical, Inc.: Net Sales
Table 158. Icu Medical, Inc.: Key Stratergies
Table 159. Jw Life Science: Company Snapshot
Table 160. Jw Life Science: Operating Segments
Table 161. Jw Life Science: Product Portfolio
Table 162. Jw Life Science: Net Sales
Table 163. Jw Life Science: Key Stratergies
Table 164. Otsuka Pharmaceutical Co., Ltd.: Company Snapshot
Table 165. Otsuka Pharmaceutical Co., Ltd.: Operating Segments
Table 166. Otsuka Pharmaceutical Co., Ltd.: Product Portfolio
Table 167. Otsuka Pharmaceutical Co., Ltd.: Net Sales
Table 168. Otsuka Pharmaceutical Co., Ltd.: Key Stratergies
Table 169. Pfizer, Inc.: Company Snapshot
Table 170. Pfizer, Inc.: Operating Segments
Table 171. Pfizer, Inc.: Product Portfolio
Table 172. Pfizer, Inc.: Net Sales
Table 173. Pfizer, Inc.: Key Stratergies
Table 174. Salius Pharma Private Limited: Company Snapshot
Table 175. Salius Pharma Private Limited: Operating Segments
Table 176. Salius Pharma Private Limited: Product Portfolio
Table 177. Salius Pharma Private Limited: Net Sales
Table 178. Salius Pharma Private Limited: Key Stratergies
Table 179. Sichuan Kelun Pharmaceutical Co. Ltd: Company Snapshot
Table 180. Sichuan Kelun Pharmaceutical Co. Ltd: Operating Segments
Table 181. Sichuan Kelun Pharmaceutical Co. Ltd: Product Portfolio
Table 182. Sichuan Kelun Pharmaceutical Co. Ltd: Net Sales
Table 183. Sichuan Kelun Pharmaceutical Co. Ltd: Key Stratergies
Table 184. Soxa Formulations & Research (Pvt.) Ltd.: Company Snapshot
Table 185. Soxa Formulations & Research (Pvt.) Ltd.: Operating Segments
Table 186. Soxa Formulations & Research (Pvt.) Ltd.: Product Portfolio
Table 187. Soxa Formulations & Research (Pvt.) Ltd.: Net Sales
Table 188. Soxa Formulations & Research (Pvt.) Ltd.: Key Stratergies
Table 189. Vifor Pharma Management Ltd.: Company Snapshot
Table 190. Vifor Pharma Management Ltd.: Operating Segments
Table 191. Vifor Pharma Management Ltd.: Product Portfolio
Table 192. Vifor Pharma Management Ltd.: Net Sales
Table 193. Vifor Pharma Management Ltd.: Key Stratergies
List of Figures
Figure 1. Mexoryl Sx (Ecamsule) Market Segmentation
Figure 2. Mexoryl Sx (Ecamsule) Market,2021-2031
Figure 3. Mexoryl Sx (Ecamsule) Market,2021-2031
Figure 4. Top Investment Pockets, by Region
Figure 5. Porter Five-1
Figure 6. Porter Five-2
Figure 7. Porter Five-3
Figure 8. Porter Five-4
Figure 9. Porter Five-5
Figure 10. Top Player Positioning
Figure 11. Mexoryl Sx (Ecamsule) Market:Drivers, Restraints and Opportunities
Figure 12. Pricing Analysis
Figure 13. Value Chain Analysis
Figure 14. Key Regulation Analysis
Figure 15. Patent Analysis by Company
Figure 16. Patent Analysis by Country
Figure 17. Mexoryl Sx (Ecamsule) Market,By Purity Level,2021(%)
Figure 18. Comparative Share Analysis of Less Than 98% Mexoryl Sx (Ecamsule) Market,2021-2031(%)
Figure 19. Comparative Share Analysis of More Than 98% Mexoryl Sx (Ecamsule) Market,2021-2031(%)
Figure 20. Mexoryl Sx (Ecamsule) Market,By Application,2021(%)
Figure 21. Comparative Share Analysis of Cosmetics Mexoryl Sx (Ecamsule) Market,2021-2031(%)
Figure 22. Comparative Share Analysis of Pharmaceuticals Mexoryl Sx (Ecamsule) Market,2021-2031(%)
Figure 23. Comparative Share Analysis of Others Mexoryl Sx (Ecamsule) Market,2021-2031(%)
Figure 24. Mexoryl Sx (Ecamsule) Market by Region,2021
Figure 25. U.S. Mexoryl Sx (Ecamsule) Market,2021-2031($Million)
Figure 26. Canada Mexoryl Sx (Ecamsule) Market,2021-2031($Million)
Figure 27. Mexico Mexoryl Sx (Ecamsule) Market,2021-2031($Million)
Figure 28. Germany Mexoryl Sx (Ecamsule) Market,2021-2031($Million)
Figure 29. United Kingdom Mexoryl Sx (Ecamsule) Market,2021-2031($Million)
Figure 30. France Mexoryl Sx (Ecamsule) Market,2021-2031($Million)
Figure 31. Spain Mexoryl Sx (Ecamsule) Market,2021-2031($Million)
Figure 32. Italy Mexoryl Sx (Ecamsule) Market,2021-2031($Million)
Figure 33. Rest of Europe Mexoryl Sx (Ecamsule) Market,2021-2031($Million)
Figure 34. China Mexoryl Sx (Ecamsule) Market,2021-2031($Million)
Figure 35. India Mexoryl Sx (Ecamsule) Market,2021-2031($Million)
Figure 36. Japan Mexoryl Sx (Ecamsule) Market,2021-2031($Million)
Figure 37. South Korea Mexoryl Sx (Ecamsule) Market,2021-2031($Million)
Figure 38. Australia Mexoryl Sx (Ecamsule) Market,2021-2031($Million)
Figure 39. Rest of Asia-Pacific Mexoryl Sx (Ecamsule) Market,2021-2031($Million)
Figure 40. Brazil Mexoryl Sx (Ecamsule) Market,2021-2031($Million)
Figure 41. Saudi Arabia Mexoryl Sx (Ecamsule) Market,2021-2031($Million)
Figure 42. South Africa Mexoryl Sx (Ecamsule) Market,2021-2031($Million)
Figure 43. Rest of LAMEA Mexoryl Sx (Ecamsule) Market,2021-2031($Million)
Figure 44. Top Winning Strategies, by Year
Figure 45. Top Winning Strategies, by Development
Figure 46. Top Winning Strategies, by Company
Figure 47. Product Mapping of Top 10 Players
Figure 48. Competitive Dashboard
Figure 49. Competitive Heatmap of Top 10 Key Players
Figure 50. L'oréal SA.: Net Sales ,($Million)
Figure 51. Skylead Pharmaceuticals & Chemicals.: Net Sales ,($Million)
Figure 52. Chemscene LLC.: Net Sales ,($Million)
Figure 53. Biosynth Carbosynth.: Net Sales ,($Million)
Figure 54. National Analytical Corporation.: Net Sales ,($Million)
Figure 55. Norna Technology Co..: Net Sales ,($Million)
Figure 56. Derma Companies.: Net Sales ,($Million)
Figure 57. Mfci Co.,Ltd.: Net Sales ,($Million)
Figure 58. Merck KGaA.: Net Sales ,($Million)
Figure 59. Parchem Fine and Specialty Chemicals.: Net Sales ,($Million)

Executive Summary

According to the report, titled, “Mexoryl SX (Ecamsule) Market," the mexoryl sx (ecamsule) market was valued at $49.5 million in 2021, and is estimated to reach $82.6 million by 2031, growing at a CAGR of 5.3% from 2022 to 2031.

Mexoryl SX (Ecamsule) is an organic compound that is added to many sunscreens to filter out UVA rays. It possesses excellent photostability, which makes it best-suited for use as an active ingredient in manufacturing anti-ageing creams, long ultraviolet (UVA) ray absorbers, sunscreens, and anti-skin cancer drugs.

The rise in concerns about skin protection against detrimental rays of the sun and improved alertness regarding skin cancer have led the customers become more linear toward using Mexoryl SX (Ecamsule)-based sunscreens. According to a report published by the Indian Ministry of Economy and Industry, the personal care and cosmetics industry is one of the fastest-growing sectors and was worth around $10.5 million in 2021. In addition, incidence of both non-melanoma and melanoma skin cancers has been increasing over the past decades where mexoryl SX (ecamsule) is widely used to produce anti-skin cancer drugs. For instance, according to a report published by the World Health Organization (WHO), around 2-3 million cases of non-melanoma skin cancers and 132,000 cases of melanoma skin cancers occur globally each year. This is anticipated to foster the demand for mexoryl (SX) ecamsule market during the forecast period.

However, lack of awareness among customers about the benefits of mexoryl SX (Ecamsule) may restrain the growth of the mexoryl SX (Ecamsule) market during the forecast period.

On the contrary, rise in R&D activities for developing a broad spectrum of sunscreens formulation where mexoryl SX (ecamsule) is widely used for photo-protection purposes in all skin types may create new opportunities for the market.

The mexoryl (SX) ecamsule market is segmented on the basis of purity level, application, and region. By purity level, the market is segregated into less than 98% and more than 98%. The more than 98% segment dominated the global market in terms of revenue in 2021, with 68.08% of the total share. This is attributed to the increasing incidence of both non-melanoma and melanoma skin cancers. Mexoryl SX (ecamsule) with more than 98% purity levels is widely used to produce anti-skin cancer drugs. This has surged the popularity of mexoryl (SX) ecamsule with more than 98% purity levels among the pharmaceutical sector.

By application, the market is divided into cosmetics, pharmaceuticals, and others. The cosmetics segment dominated the global market in terms of revenue in 2021, with 71.92% of the total share. This is attributed to rising concerns about skin protection against detrimental rays of the sun and improved alertness regarding skin cancer have led the customers become more linear toward using mexoryl SX (ecamsule)-based sunscreens and other cosmetic formulations. This factor may fuel the demand for mexoryl (SX) ecamsule for cosmetics applications.

Region-wise, the mexoryl (SX) ecamsule market is analyzed across North America, Europe, Asia-Pacific, and LAMEA. The Europe mexoryl (SX) ecamsule market size is projected to grow at the highest CAGR during the forecast period, owing to increasing proportion of elder population in countries such as Italy and Spain, which in turn has surged the demand for anti-ageing creams where mexoryl SX (ecamsule) acts as an active ingredient in manufacturing various anti-ageing formulations. For instance, according to a report published by Population Reference Bureau, Italy ranks second in world’s oldest populations (aged 65 and above) with 23% of the population with age 65 and above. This factor has augmented the growth of the mexoryl (SX) ecamsule market in the Europe region.

Key players operating in the global mexoryl (SX) ecamsule market include Biosynth Carbosynth, ChemScene LLC, Derma Company, National Analytical Corporation, Norna Technology Co., Skylead Pharmaceuticals & Chemicals, L'Oréal S.A., and MFCI CO., LTD (Hubei Meifeng Chemical Co., Ltd.).

COVID-19 Analysis

  • The novel coronavirus is an incomparable global pandemic that has spread to over 180 countries and caused huge losses of lives and the economy around the globe. The mexoryl SX (ecamsule) market has little impact due to the wake of the COVID-19 pandemic, owing to the disruptions in the supply chain for various personal hygiene, and medical products. Furthermore, to control the surge of novel coronavirus cases, there is a drastic shift of investments from other sectors toward healthcare. Moreover, several ecamsule manufacturing companies have either shut down or shrank their operations due to the risk of infection among the workforce. This has temporarily hampered the demand and supply chain of air-laid products amid the COVID-19 pandemic. However, growth in awareness related to personal care activities has surged the demand for mexoryl SX (ecamsule)-based sunscreens, anti-ageing creams, and other cosmetic products during the COVID-19 pandemic, which in turn has increased the demand for mexoryl SX (ecamsule) market. Furthermore, several ecamsule manufacturing companies have adopted safety strategies and techniques, which in turn may increase the demand for air-laid product as the market starts stabilizing.
  • In 2020, mexoryl SX (ecamsule) prices were higher in Asia-Pacific. The price rise was, due to continued regional demand trends and tight product availability. Firm downstream air-laid product’s demand and stronger upstream costs are expected to sustain the price gain.
  • However, the mexoryl SX (ecamsule) market is expected to recover rapidly post COVID-19 situation due to its increased dependency over pharmaceutical other sectors. For instance, according to an article published by Financial Express, the Indian pharmaceutical industry registered a growth of 15% in 2021, and is expected to grow at an average annual growth rate of 18.6% by 2025. This is expected to enhance the performance of the mexoryl SX (ecamsule) post- COVID-19 scenario.

Key Findings of the Study

  • By purity level, the more than 98% segment is estimated to display the highest growth rate, in terms of revenue, registering a CAGR of 5.4% from 2022 to 2031.
  • By application, the cosmetics segment is estimated to display the highest growth rate, in terms of revenue, registering a CAGR of 5.4% from 2022 to 2031.
  • North America garnered the highest share of 32.93% in 2021, in terms of revenue, growing at a CAGR of 5.2%.

Companies Mentioned

  • L'oréal S.A.
  • Skylead Pharmaceuticals & Chemicals
  • Chemscene LLC
  • Biosynth Carbosynth
  • National Analytical Corporation
  • Norna Technology Co.
  • Derma Companies
  • Mfci Co.Ltd
  • Merck Kgaa
  • Parchem Fine and Specialty Chemicals

Methodology

The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.

They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.

They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:

  • Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic news articles and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast

Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.

Loading
LOADING...

Table Information